{"id":"acenocoumarol-vka","safety":{"commonSideEffects":[{"rate":"2-4","effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Bruising"},{"rate":"1-2","effect":"Gastrointestinal bleeding"},{"rate":"0.5-1","effect":"Intracranial hemorrhage"},{"rate":"0.1-0.5","effect":"Skin necrosis"}]},"_chembl":{"chemblId":"CHEMBL397420","moleculeType":"Small molecule","molecularWeight":"353.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acenocoumarol is a vitamin K antagonist (VKA) that works by inhibiting the vitamin K epoxide reductase complex, which is essential for the carboxylation and activation of vitamin K-dependent coagulation factors. This leads to decreased synthesis of functional factors II, VII, IX, and X, resulting in prolonged prothrombin time and reduced thrombotic risk. It is used for anticoagulation in conditions requiring long-term thromboembolic prevention.","oneSentence":"Acenocoumarol inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K recycling, thereby reducing thrombin generation and preventing blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:00.974Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) prevention and treatment"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Post-myocardial infarction thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT02286414","phase":"","title":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Atrial Fibrillation","enrollment":159},{"nctId":"NCT04099238","phase":"","title":"Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-10-01","conditions":"Atrial Fibrillation","enrollment":3739},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT02942576","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-03-21","conditions":"Atrial Fibrillation","enrollment":632},{"nctId":"NCT03532724","phase":"","title":"Clinical Outcomes From Patient Self-management of Antivitamin K Treatment","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2017-11-01","conditions":"Self Management of Oral Anticoagulation With VKA Therapy","enrollment":927},{"nctId":"NCT03462446","phase":"","title":"Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-01","conditions":"Atrial Fibrillation","enrollment":249},{"nctId":"NCT01727453","phase":"PHASE4","title":"Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2011-12","conditions":"Acute Gastrointestinal Bleeding","enrollment":40},{"nctId":"NCT01674647","phase":"PHASE3","title":"Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":"Atrial Fibrillation","enrollment":1504},{"nctId":"NCT00062803","phase":"PHASE3","title":"SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Pulmonary Embolism","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":136,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Acenocoumarol VKA","genericName":"Acenocoumarol VKA","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acenocoumarol inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K recycling, thereby reducing thrombin generation and preventing blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) prevention and treatment, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}